Page last updated: 2024-11-04

lipoxin a4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lipoxin A4: an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lipoxin A4 : A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280914
CHEMBL ID392438
CHEBI ID6498
MeSH IDM0120656

Synonyms (43)

Synonym
6r-lxa4
(5s,6r,15s)-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid
(5s,6r,7e,9e,11z,13e,15s)-5,6,15-trihydroxyeicosa-7,9,11,13-tetraenoic acid
CHEBI:6498 ,
5(s),6(r),15(s)-trihydroxyeicosa-7e,9e,11z,13e-tetraenoic acid
(5s,6r,7e,9e,11z,13e,15s)-5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid
(5s,6r,7e,9e,11z,13e,15s)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
5s,6r,15s-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid
gtpl1034
LMFA03040001
5s,6r-lipoxina4
IDI1_033848
BSPBIO_001378
(7e,9e,11z,13e)-(5s,6r,15s)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
5s,6r,15s-trihydroxy-7e,9e,11z,13e-eicosatetraenoic acid
lxa4
lipoxin a4
C06314
NCGC00161280-01
NCGC00161280-02
NCGC00161280-03
5,6,15-trihete
HMS1989E20
CHEMBL392438
BML1-E11
HMS1361E20
HMS1791E20
7,9,11,13-eicosatetraenoicacid, 5,6,15-trihydroxy-, (5s,6r,7e,9e,11z,13e,15s)-
HMS3402E20
DTXSID6040535
unii-f7c6j3d79j
f7c6j3d79j ,
5s,6r,15s-trihydroxy-7e,9e,11z,13e-eicosatetraenoate
lipoxin a
Q27082450
(7e,9e,11z,13e)-(5s,6r,15s)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoate
sr-01000946984
SR-01000946984-1
bdbm50520816
HY-113509
7,9,11,13-eicosatetraenoic acid, 5,6,15-trihydroxy-, (5s,6r,7e,9e,11z,13e,15s)-
CS-0062443
AKOS040755014

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In conclusion, ESMR therapy is safe and effective in most but not all patients with CAD and heart failure."( Effectiveness and Safety of Extracorporeal Shockwave Myocardial Revascularization in Patients With Refractory Angina Pectoris and Heart Failure.
Alexanderson-Rosas, E; Amezcua-Guerra, LM; Azar-Manzur, F; Bojalil, R; Brianza-Padilla, M; Carvajal-Juárez, I; González-Pacheco, H; Gopar-Nieto, R; Hernández, S; López-Mora, E; Márquez-Velasco, R; Martínez-Sánchez, C; Massó, F; Paez-Arenas, A; Sandoval, J; Venegas-Román, A, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Native LX are rapidly inactivated in vivo, and stable analogs of LXA(4), LXB(4), and ATL have been synthesized that possess enhanced bioavailability and potency as anti-inflammatory eicosanoids."( Lipoxins: pro-resolution lipid mediators in intestinal inflammation.
Brady, HR; Godson, C; Goh, J; Macmathuna, P, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" The LxA4 dose-response curve was parallel to that of leukotriene D4 (LTD4) with LxA4 being approximately 10,000 fold less potent than LTD4."( The contractile activities of lipoxin A4 and lipoxin B4 for guinea-pig airway tissues.
Crea, AE; Jacques, CA; Lee, TH; Spur, BW, 1988
)
0.27
" Dose-response studies showed that both lipoxin A and lipoxin B inhibit, at submicromolar concentrations (ID50 10(-7) M), NK cell activity assayed against K562 target cells."( Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding.
Ng, J; Ramstedt, U; Samuelsson, B; Serhan, CN; Wigzell, H, 1985
)
0.27
" Dose-response studies showed that biologically derived LXA and synthetic LXA were equally effective in inhibiting NK cell cytotoxicity."( Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: studies on stereospecificity of inhibition and mode of action.
Nicolaou, KC; Ramstedt, U; Samuelsson, B; Serhan, CN; Webber, SE; Wigzell, H, 1987
)
0.27
" FMLP-stimulated CD11b upregulation as well as homotypic aggregation of PMN was inhibited by LXA4 (which at 10(-9) M gave approximately 1 log unit shift to the right in the FMLP dose-response curve)."( Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction.
Fiore, S; Serhan, CN, 1995
)
0.29
" LXA4, caused an increase in particulate PKC-dependent histone phosphorylating activity with a bell-shaped dose-response fashion; maximal stimulation was observed at 10 nM LXA4."( Stimulation of protein kinase C redistribution and inhibition of leukotriene B4-induced inositol 1,4,5-trisphosphate generation in human neutrophils by lipoxin A4.
Chung-a-on, KO; Lee, TH; Soyombo, O; Spur, BW, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
lipoxinA nonclassic icosanoid and signalling molecule that has four conjugated double bonds and is derived from arachidonic acid.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
hydroxy polyunsaturated fatty acidAny polyunsaturated fatty acid carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Biosynthesis of specialized proresolving mediators (SPMs)13107
Synthesis of Lipoxins (LX)616
Eicosanoid metabolism via lipooxygenases (LOX)040
Folic acid network070
Relationship between glutathione and NADPH036
Eicosanoid metabolism via lipoxygenases (LOX)040
Selenium micronutrient network095
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)0.00010.00011.97318.0000AID1817450
N-formyl peptide receptor 2Homo sapiens (human)IC50 (µMol)0.01190.00170.01190.0263AID1585247; AID1585248; AID1585249; AID1585250; AID1585251; AID1585252
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC50 (µMol)0.00010.00011.80888.0000AID1817450
Transcription factor p65Homo sapiens (human)IC50 (µMol)0.00010.00011.89818.8000AID1817450
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (125)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
chemotaxisN-formyl peptide receptor 2Homo sapiens (human)
cell adhesionN-formyl peptide receptor 2Homo sapiens (human)
cell surface receptor signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
calcium-mediated signalingN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of superoxide anion generationN-formyl peptide receptor 2Homo sapiens (human)
defense response to bacteriumN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of innate immune responseN-formyl peptide receptor 2Homo sapiens (human)
negative regulation of inflammatory responseN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of phagocytosisN-formyl peptide receptor 2Homo sapiens (human)
positive chemotaxisN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of monocyte chemotaxisN-formyl peptide receptor 2Homo sapiens (human)
cellular response to amyloid-betaN-formyl peptide receptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationN-formyl peptide receptor 2Homo sapiens (human)
inflammatory responseN-formyl peptide receptor 2Homo sapiens (human)
complement receptor mediated signaling pathwayN-formyl peptide receptor 2Homo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
amyloid-beta bindingN-formyl peptide receptor 2Homo sapiens (human)
G protein-coupled receptor activityN-formyl peptide receptor 2Homo sapiens (human)
scavenger receptor bindingN-formyl peptide receptor 2Homo sapiens (human)
protein bindingN-formyl peptide receptor 2Homo sapiens (human)
signaling receptor activityN-formyl peptide receptor 2Homo sapiens (human)
complement receptor activityN-formyl peptide receptor 2Homo sapiens (human)
N-formyl peptide receptor activityN-formyl peptide receptor 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmN-formyl peptide receptor 2Homo sapiens (human)
plasma membraneN-formyl peptide receptor 2Homo sapiens (human)
membraneN-formyl peptide receptor 2Homo sapiens (human)
specific granule membraneN-formyl peptide receptor 2Homo sapiens (human)
tertiary granule membraneN-formyl peptide receptor 2Homo sapiens (human)
ficolin-1-rich granule membraneN-formyl peptide receptor 2Homo sapiens (human)
plasma membraneN-formyl peptide receptor 2Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1585269Anti-inflammatory activity in zymosan-induced C57BL/6J mouse peritonitis model assessed as reduction in PMN leukocytes level in peritoneal cavity at 125 ng, ip pretreated for 30 mins followed by zymosan treatment and redosing of test compound at 1 hr post2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585248Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IFNgamma secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochem2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585221Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-1beta secretion at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585210Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by luciferas2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID303368Increase in human THP1 cells mediated phagocytosis of apoptotic polymorphonuclear leukocytes at 0.1 pM to 1 nM after 15 mins2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities.
AID1585250Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in TNFalpha secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochem2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585205Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-12 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by lucifera2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585209Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-8 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by luciferas2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585230Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-12p70 secretion at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585271Anti-inflammatory activity in zymosan-induced C57BL/6J mouse peritonitis model assessed as PMN leukocytes level in peritoneal cavity at 125 ng, ip pretreated for 30 mins followed by zymosan treatment and redosing of test compound at 1 hr post zymosan addi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817462Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1585240Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring TNFalpha secretion at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817451Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release at 0.01 to 100 nM pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1585206Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by lucifera2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID317225Stability assessed as rate of NADH formation in presence of eicosanoid oxido-reductase relative to lipoxin A42008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties.
AID1585252Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IL-6 secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemilum2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585235Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IFNgamma secretion at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817474Induction of phagocytosis in human THP-1-MF0 macrophages at 100 nM pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
AID1585227Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-6 secretion at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemilumin2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585260Agonist activity at ALX/FPR2 (unknown origin) expressed in HEK293 cells co-expressing Galphaq assessed as induction of intracellular calcium accumulation at 0.01 nM to 100 nM by Fluo-4 dye based fluorescence spectrophotometric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585211Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-6 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by luciferas2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585241Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring TNFalpha secretion at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817491Inhibition of LPS-induced NF-kappaB activation in human THP-1 monocytes expressing luciferase gene at 0.01 to 100 nM pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by bioluminescence analysis
AID1585247Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation pretreated for 30 mins followed by LPS stimulation for 24 hrs by luciferase reporter gene assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585226Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-6 secretion at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemilumin2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817471Inhibition of TNFalpha-stimulated NF-kappaB activity (unknown origin) expressed in mouse primary smooth muscle cells at 0.1 nM pretreated for 30 mins followed by TNFalpha stimulation and incubated for 24 hrs by SEAP reporter gene assay
AID1585225Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-6 secretion at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemilumi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585207Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-10 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by lucifera2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585232Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-12p70 secretion at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585237Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IFNgamma secretion at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585251Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IL-1beta secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochem2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585222Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-1beta secretion at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585263Induction of intracellular calcium accumulation in HEK293 cells at 0.01 nM to 100 nM by Fluo-4 dye based fluorescence spectrophotometric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585208Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring NF-kB activation level at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by luciferas2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585220Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-1beta secretion at 10'-11 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemi2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817476Induction of phagocytosis in human THP-1-MF0 macrophages pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
AID1817490Agonist activity at ALX/FPR2 receptor (unknown origin) expressed in HEK-293 cells assessed as increase in calcium flux at 0.01 to 100 nM by Fluo-4 staining based assay
AID1817454Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1817473Induction of phagocytosis in human THP-1-MF0 macrophages assessed as fold increase in phagocytosis at 1 fM to 1 uM pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
AID1585204Anti-inflammatory activity in zymosan-induced C57BL/6J mouse peritonitis model assessed as reduction in total cell count in peritoneal cavity at 125 ng, ip pretreated for 30 mins followed by zymosan treatment and redosing of test compound at 1 hr post zym2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585242Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring TNFalpha secretion at 10'-7 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID360431Activity of recombinant 15-prostaglandin dehydrogenase/eicosanoid oxidoreductase assessed as NADH formation at 20 uM after 25 mins2007The Journal of biological chemistry, Mar-30, Volume: 282, Issue:13
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation.
AID303374Increase in human THP1 cells mediated phagocytosis of apoptotic polymorphonuclear leukocytes at 1 nM in presence of pan-FPR/ALXR antagonist Boc22007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities.
AID1585249Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IL-12p70 secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochem2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585231Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IL-12p70 secretion at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817492Anti-inflammatory activity against human THP-1 monocytes assessed as increase in LPS-induced IL-8 release at 1 nM by multiplex chemiluminescence detection method
AID1585267Anti-inflammatory activity in zymosan-induced C57BL/6J mouse peritonitis model assessed as total cell count in peritoneal cavity at 125 ng, ip pretreated for 30 mins followed by zymosan treatment and redosing of test compound at 1 hr post zymosan addition2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585244Cytotoxicity against mouse J774.1 cells assessed as cell viability by MTS assay relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1585236Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring IFNgamma secretion at 10'-9 M pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemil2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817459Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release at 0.01 nM to 100 nM pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1817450Inhibition of LPS-induced NF-kappaB activation in human THP-1 monocytes expressing luciferase gene pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by bioluminescence analysis
AID317224Stability assessed as rate of NADH formation in presence of eicosanoid oxido-reductase2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties.
AID1585215Activation of Luc-fused NFkB (unknown origin) expressed in non-stimulated human THP1 cells assessed as relative luminescence unit at 10'-9 M after 24 hrs by luciferase reporter gene assay (Rvb = 100%)2019European journal of medicinal chemistry, Jan-15, Volume: 162Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
AID1817455Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release at 0.01 nM to 100 nM pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1817458Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
AID1817475Induction of phagocytosis in human THP-1-MF0 macrophages at 1 uM pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1345806Human FPR2/ALX (Leukotriene receptors)1992The Journal of biological chemistry, Aug-15, Volume: 267, Issue:23
Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils.
AID1345806Human FPR2/ALX (Leukotriene receptors)2010Proceedings of the National Academy of Sciences of the United States of America, Jan-26, Volume: 107, Issue:4
Resolvin D1 binds human phagocytes with evidence for proresolving receptors.
AID1345806Human FPR2/ALX (Leukotriene receptors)1994The Journal of experimental medicine, Jul-01, Volume: 180, Issue:1
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.
AID1346936Human GPR32 (Class A Orphans)2010Proceedings of the National Academy of Sciences of the United States of America, Jan-26, Volume: 107, Issue:4
Resolvin D1 binds human phagocytes with evidence for proresolving receptors.
AID1345856Mouse FPR3 (Formylpeptide receptors)1997The Journal of experimental medicine, May-05, Volume: 185, Issue:9
Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (808)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (8.17)18.7374
1990's126 (15.59)18.2507
2000's186 (23.02)29.6817
2010's352 (43.56)24.3611
2020's78 (9.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (2.04%)5.53%
Reviews85 (10.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.12%)0.25%
Other730 (87.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]